Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for macrophage activation syndrome secondary to Still's disease or systemic lupus erythematosus
CTR20221155Phase 3Completed
- Sponsor
- 不适用/ 苏庇医药（广州）有限公司
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of emapalumab in macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD), systemic lupus erythematosus (SLE), sponsored by 不适用/ 苏庇医药（广州）有限公司. Started Aug 2023; status: completed.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)adult-onset Still's disease (AOSD)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20221155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221155.